STING agonist-4
Based on 8 publication(s) in Google Scholar
STING agonist-4 is an stimulator of Interferon Genes (STING) receptor agonist with an apparent inhibitory constant (IC50) of 20 nM. STING agonist-4 is a two symmetry-related amidobenzimidazole (ABZI)-based compound to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.52%
- No. CAS: 2138300-40-8
- Fòrmula: C34H38N12O4
- Peso molecular:678.74
-
Almacenamiento:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-148068
STING agonist-20STING Agonist -
HY-147010
STING agonist-12STING Activator -
HY-112921
diABZI STING agonist-1 (tautomerism)STING Agonist -
HY-112693
H-151STING Antagonist -
HY-112906
C-176STING Inhibitor -
HY-136927
MSA-2STING Agonist -
HY-10087
NavitoclaxBcl-2/Bcl-xL/Bcl-w Inhibitor -
HY-110385
cGAMP disodiumSTING Activator -
HY-141514
MSA-2 dimerSTING Agonist -
HY-12885B
2’3’-c-di-AM(PS)2 (Rp,Rp) ammonium saltSTING Agonist -
HY-P9917
TocilizumabIL-6R Neutralizing Antibody -
HY-123963
C-178STING Inhibitor
Publications Citing Use of MedChemExpress (MCE) STING agonist-4
More- Bioact Mater. 2025 Jun 10:52:182-199. [Abstract]
- Biomaterials. 2022 Aug:287:121673. [Abstract]
- Chem Eng J. 2024 Mar 1, 483 149223.
- Phytomedicine. 2023 Aug:117:154922. [Abstract]
- Free Radic Biol Med. 2025 Aug 20:240:373-383. [Abstract]
- Eur J Med Chem. 2023 Mar 15:250:115184. [Abstract]
- Cell Rep Methods. 2025 Jul 21;5(7):101106. [Abstract]
- Sci Rep. 2024 May 21;14(1):11593. [Abstract]
Actividad biológica
Descripciòn
IC50 & Target
IC50: 20 nM (STING agonist-4)[1]
In Vitro
STING agonist-4 (Compound 2) (0.3-30 μM; 2 hours) causes phosphorylation of IRF3 and STING that is inhibited by the TBK1 inhibitor BX795 and induces dose-dependent secretion of IFN-β with an EC50 of 3.1 μM[1]. STING agonist-4 (Compound 2) (0.001 nM-1 μM) inhibits binding of full-length STING to the solid support with an apparent dissociation constant (Kd) of approximately 1.6 nM[1]. STING agonist-4 (Compound 2) (0-100 μM) is 18-fold more potent than cGAMP (an endogenous STING ligand), with an EC50 of 53.9 μM[1]. STING agonist-4 (Compound 2) (3 μM; 4 hours) promotes production of interferon γ-induced protein 10 (IP-10), IL-6 and TNF-α by a mechanism that is dependent on STING-mediated activation of TBK1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human peripheral blood mononuclear cells (PBMCs)
-
Concentration:0.3 μM, 1 μM, 3 μM, 10 μM and 30 μM
-
Incubation Time:2 hours
-
Result:Caused phosphorylation of IRF3 and STING and induced secretion of IFN-β.
Chemical Information
-
No. CAS 2138300-40-8
-
Appearance Solid
-
Peso molecular 678.74
-
Fòrmula C34H38N12O4
-
Color White to gray
-
SMILES
O=C(C1=CC=C2N(CCCCN3C(NC(C4=CC(C)=NN4CC)=O)=NC5=CC(C(N)=O)=CC=C35)C(NC(C6=CC(C)=NN6CC)=O)=NC2=C1)N
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Bioact Mater
Near-infrared light-induced photothermal and immunotherapy system for lung cancer bone metastasis treatment with simultaneous bone repair. [Abstract]2025 Jun 10:52:182-199. PMID: 40538765 -
Biomaterials
2022 Aug:287:121673. PMID: 35839587 -
-
Phytomedicine
Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING/NLRP3 signalling pathway. [Abstract]2023 Aug:117:154922. PMID: 37321078 -
Free Radic Biol Med
Exercise training ameliorates high-fat diet-induced skeletal muscle atrophy and ferroptosis via downregulation of STING. [Abstract]2025 Aug 20:240:373-383. PMID: 40846100 -
Eur J Med Chem
Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist. [Abstract]2023 Mar 15:250:115184. PMID: 36758305 -
Cell Rep Methods
A fluorescent STING ligand sensor for high-throughput screening of compounds that can enhance tumor immunotherapy. [Abstract]2025 Jul 21;5(7):101106. PMID: 40669456 -
Sci Rep
Treg-derived TGF-β1 dampens cGAS-STING signaling to downregulate the expression of class I MHC complex in multiple myeloma. [Abstract]2024 May 21;14(1):11593. PMID: 38773213
Solvente y solubilidad
In Vitro:
DMSO : 1 mg/mL (1.47 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* STING agonist-4 is usually formulated as a suspension.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.1 mg/mL (0.15 mM); Clear solution
This protocol yields a clear solution of ≥ 0.1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (1.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.1 mg/mL (0.15 mM); Clear solution
This protocol yields a clear solution of ≥ 0.1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (1.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4733 mL | 7.3666 mL | 14.7332 mL | 36.8330 mL |
STING agonist-4 Related Classifications
HY-123943 Related Classifications
Powered by Bioz